AC Immune SA
Close on Oct 19, 2026
About AC Immune
Pharmaceutical Preparations, SIC 2834
AC Immune SA is a clinical-stage biopharmaceutical company that discovers and develops precision therapeutics and diagnostic agents for neurodegenerative disorders, particularly Alzheimer’s disease and Parkinson’s disease. The company's pipeline comprises active immunotherapies, brain-penetrant small molecule inhibitors, monoclonal antibodies, and diagnostic positron emission tomography imaging tracers. These investigational candidates target misfolded pathological proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43. AC Immune operates primarily through research, development, and licensing arrangements with major global pharmaceutical companies, which serve as commercialization partners alongside clinical trial participants.
The company is headquartered in Ecublens at the EPFL Innovation Park in Lausanne, Switzerland. Its operations and clinical research activities extend internationally, with clinical trials conducted across Europe and North America, including sites in the United States, the United Kingdom, the Netherlands, and Spain. AC Immune collaborates with multinational healthcare corporations across global markets to advance its therapeutic and diagnostic pipelines.
Summary of the business section of AC Immune's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AC Immune SA
- Founded
- 2003
- Headquarters
- 1015 Lausanne, V8
- Address
- Epfl Innovation Park, Building B 00000
- Phone
- 41 21 345 91 21
- Website
- acimmune.com
- Employees
- 122, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers SA, Lausanne, Switzerland
Stock & identifiers
- Ticker
- ACIU
- Exchange
- Nasdaq
- IPO date
- Sep 23, 2016
- Shares outstanding
- 102M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1651625
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Martin Zuegel | Interim CEO, Director | 71,408 |
| Andrea Pfeifer | Chief Executive Officer, Director | 3,834,288 |
| Piergiorgio Donati | Chief Operating Officer | 141,120 |
| Christopher James Roberts | Chief Financial Officer | 155,382 |
| Carl Howard June | Director | 67,556 |
| Roy Ervin Twyman | Director | 92,556 |
| Monika Buetler | Director | 71,656 |
| Renee Aguiar-Lucander | Director | 51,136 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 122 employees, 32 of whom were part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 23, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 23, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |